These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 23908493)

  • 21. Genotypic resistance and HIV-1 subtype in Brazilian children on dual and triple combination therapy.
    Machado ES; Lambert JS; Watson DC; Afonso AO; da Cunha SM; Nogueira SA; Caride E; Oliveira RH; Sill AM; DeVico A; Tanuri A
    J Clin Virol; 2004 May; 30(1):24-31. PubMed ID: 15072750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Optimal antiretroviral therapy: HIV-1 treatment strategies to avoid and overcome drug resistance.
    Grant PM; Zolopa AR
    Curr Opin Investig Drugs; 2010 Aug; 11(8):901-10. PubMed ID: 20721832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual nucleoside reverse transcriptase inhibitor therapy in the combination antiretroviral therapy era and predictors of discontinuation or switch to combination antiretroviral therapy.
    Selinger-Leneman H; Matheron S; Mahamat A; Moreau J; Costagliola D; Abgrall S;
    J Acquir Immune Defic Syndr; 2008 Feb; 47(2):206-11. PubMed ID: 17971717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
    Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri AC; Phillips AN
    J Infect Dis; 1999 Aug; 180(2):530-3. PubMed ID: 10395876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
    Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF
    Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HIV-1 infection and pregnancy in young women in Brazil: socioeconomic and drug resistance profiles in a cross-sectional study.
    Lima YA; Reis MN; Cardoso LP; Stefani MM
    BMJ Open; 2016 Jul; 6(7):e010837. PubMed ID: 27381205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low primary and secondary HIV drug-resistance after 12 months of antiretroviral therapy in human immune-deficiency virus type 1 (HIV-1)-infected individuals from Kigali, Rwanda.
    Rusine J; Asiimwe-Kateera B; van de Wijgert J; Boer KR; Mukantwali E; Karita E; Gasengayire A; Jurriaans S; de Jong M; Ondoa P
    PLoS One; 2013; 8(8):e64345. PubMed ID: 23950859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of HIV-1 subtype on virologic and immunologic response to starting highly active antiretroviral therapy.
    Geretti AM; Harrison L; Green H; Sabin C; Hill T; Fearnhill E; Pillay D; Dunn D;
    Clin Infect Dis; 2009 May; 48(9):1296-305. PubMed ID: 19331585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy.
    Wu H; Connick E; Kuritzkes DR; Landay A; Spritzler J; Zhang B; Spear GT; Kessler H; Lederman MM;
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1231-40. PubMed ID: 11559422
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa.
    Gottlieb GS; Badiane NM; Hawes SE; Fortes L; Toure M; Ndour CT; Starling AK; Traore F; Sall F; Wong KG; Cherne SL; Anderson DJ; Dye SA; Smith RA; Mullins JI; Kiviat NB; Sow PS;
    Clin Infect Dis; 2009 Feb; 48(4):476-83. PubMed ID: 19143530
    [TBL] [Abstract][Full Text] [Related]  

  • 32. AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.
    Smurzynski M; Collier AC; Koletar SL; Bosch RJ; Wu K; Bastow B; Benson CA
    HIV Clin Trials; 2008; 9(4):269-82. PubMed ID: 18753121
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].
    Rey D; Schmitt MP; Hess-Kempf G; Krantz V; Partisani M; Bernard-Henry C; Lang JM
    Pathol Biol (Paris); 2001 Sep; 49(7):559-66. PubMed ID: 11642019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy.
    Stephan C; Bartha V; Herrmann E; von Hentig N; Khaykin P; Knecht G; Gute P; Brodt HR; Stürmer M; Berger A; Bickel M
    Med Microbiol Immunol; 2013 Apr; 202(2):117-24. PubMed ID: 22983722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 36. Human immunodeficiency virus type 1 (HIV-1) genotyping in Rio de Janeiro, Brazil: assessing subtype and drug-resistance associated mutations in HIV-1 infected individuals failing highly active antiretroviral therapy.
    Couto-Fernandez JC; Silva-de-Jesus C; Veloso VG; Rachid M; Gracie RS; Chequer-Fernandez SL; Oliveira SM; Arakaki-Sanchez D; Chequer PJ; Morgado MG
    Mem Inst Oswaldo Cruz; 2005 Feb; 100(1):73-8. PubMed ID: 15867968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy.
    Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D
    JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiretroviral therapy for HIV-2 infected patients.
    Smith NA; Shaw T; Berry N; Vella C; Okorafor L; Taylor D; Ainsworth J; Choudhury A; Daniels RS; El-Gadi S; Fakoya A; Moyle G; Oxford J; Tedder R; O'Shea S; de Ruiter A; Breuer J
    J Infect; 2001 Feb; 42(2):126-33. PubMed ID: 11531319
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunologic dynamics in hemophiliac patients infected with hepatitis C virus and human immunodeficiency virus: influence of antiretroviral therapy.
    Yokozaki S; Takamatsu J; Nakano I; Katano Y; Toyoda H; Hayashi K; Hayakawa T; Fukuda Y
    Blood; 2000 Dec; 96(13):4293-9. PubMed ID: 11110704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.